Objective: To determine the antitumor and antimetastatic effects of plasmid pcDNA3. 1-IP10 complexed with cationic liposome (DOTAP:CHOL) in mice with 4T1 breast cancer.
Methods: BALB/c mice model with 4T1 breast cancer was established. Thirty six mice with 4T1 breast cancers were divided randomly into three groups, which were intravenously injected with normal saline (200 microL), Lip-null (50 microg DNA, 200 microL) and Lip-IP10 (50 microg DNA, 200 microL) respectively every five days for six doses. The size of the tumors, the number of lung metastasis noduls and survival time were measured. Four mice from each group were sacrificed 43 days after tumor implantation. The tumor microvascula densities (MVD) were detected by immunohistochemical staining.
Results: Lip-IP10 inhibited the growth of tumor and the formation of lung metastasis neoplasm (P < 0.05). The Lip-IP10 group had a median of 3 lung metastasis nodules, less than the NS group (45) and Lip-null group (40) (P < 0.05). Lip-IP10 significantly prolonged the survival time of the tumor-bearing mice (P < 0.05). The histomorphometric analysis revealed a decreased MVD in the Lip-IP10 group (21.50 +/- 15.41 vs. 44.25 +/- 5.51 for the NS group and 43.45 +/- 4.21 for the Lip-null group, P < 0.05).
Conclusion: IP10 encapsulated in cationic liposome inhibits the growths and metastases of 4T1 breast cancers, which is based on the mechanism of IP10 inhibiting tumor angiogenesis.
Download full-text PDF |
Source |
---|
J Ethnopharmacol
January 2025
Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China. Electronic address:
Ethnopharmacological Relevance: Triple-negative breast cancer (TNBC) represents the most aggressive subtype of breast cancer, featuring a high proportion of cancer stem cells (CSCs) and the poorest clinical outcomes. Taraxacum mongolicum Hand. -Mazz.
View Article and Find Full Text PDFMol Cell Endocrinol
January 2025
Department of Nutrition and Food Safety, School of Public Health, Nanjing Medical University, Nanjing 211166, China. Electronic address:
Bisphenol A (BPA), a commonly used plastic additive, is believed to cause obesity. As an environmental endocrine disruptor, BPA is closely associated with the onset and progression of BC. However, the molecular mechanisms underlying the promotion of breast cancer by BPA remain unclear.
View Article and Find Full Text PDFMaterials (Basel)
January 2025
Radiochemical Studies Laboratory, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Patriarchou Grigoriou and 27 Neapoleos Street, 15341 Athens, Greece.
Due to their intriguing emission profile, Terbium-161 (Tb) radiopharmaceuticals seem to bring significant advancement in theranostic applications to cancer treatment. The combination of Tb with nanoscale brachytherapy as an approach for cancer treatment is particularly advantageous and promising. Herein, we propose the application of a hybrid nanosystem comprising gold decorated (Au@TADOTAGA) iron oxide nanoflowers as a form of injectable nanobrachytherapy for the local treatment of breast cancer.
View Article and Find Full Text PDFInt J Mol Sci
January 2025
Molecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37132, USA.
The autotaxin-lysophosphatidic acid receptor (ATX-LPAR) signaling axis is pivotal in various clinical conditions, including cancer and autoimmune disorders. This axis promotes tumorigenicity by interacting with the tumor microenvironment, facilitating metastasis, and conceding antitumor immunity, thereby fostering resistance to conventional cancer therapies. Recent studies highlight the promise of ATX/LPAR inhibitors in combination with conventional chemotherapeutic drugs to overcome some forms of this resistance, representing a novel therapeutic strategy.
View Article and Find Full Text PDFCancers (Basel)
January 2025
Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie National Research Institute of Oncology, 44-102 Gliwice, Poland.
: The stimulator of interferon genes (STING) is currently accepted as a relevant target for anti-cancer therapies. Besides encouraging results showing STING agonist-induced tumor growth inhibition, in some types of tumors the effect is less prominent. We hypothesized that higher STING levels in cancer cells and the possibility of its activation determine a greater anti-cancer response.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!